Will there be fever symptoms during treatment with gosatuzumab (Todavi)?

Gosatuzumab (Trodelvy) is an antibody drug used to treat advanced triple-negative breast cancer (TNBC) and certain other types of cancer. It is an antibody drug conjugate (ADC) that combines an antibody with a chemotherapy drug (such as irinotecan) to release the drug while targeting tumor cells, thereby improving the therapeutic effect. However, gosatuzumab may cause some side effects during treatment, including fever.

The cause of fever symptoms during gosatuzumab treatment may be related to the immune response to the drug. As a targeted therapy, gosatuzumab induces an immune system response by binding to antigens on tumor cells. During this process, the immune system may react to the drug, causing an increase in body temperature that manifests as fever. This fever is often one of the common side effects of treatment, especially during the first few doses of the drug.

Specifically, febrile symptoms during gosatuzumab treatment are usually mild to moderate fever, with body temperature usually between 37.5°C and 38.5°C. In most cases, fever is temporary and symptoms decrease as treatment continues. For some patients, fever symptoms resolve spontaneously within a few days without requiring special intervention. However, if fever persists for an extended period of time or if body temperature rises significantly, further medical intervention may be required.
To effectively manage fever symptoms during gosatuzumab treatment, doctors often recommend patients use fever-reducing medications such as acetaminophen (such as acetaminophen) to relieve elevated body temperatures. In addition, doctors will regularly monitor the patient's temperature to evaluate for other more serious complications, such as infection or drug allergic reaction. If the fever is accompanied by other serious symptoms (such as chills, fatigue, shortness of breath, etc.), the patient should seek medical treatment in time.
Reference: https://www.trodelvy.com/